# Cardiac Dimensions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiac-dimensions

- Industry: Medical Devices & Equipment
- Headquarters: Kirkland, US
- Website: www.cardiacdimensions.com
- Total disclosed funding: $168M
- Latest round: Series E (Mar 20, 2025)
- Investors on record: 16

## About

Cardiac Dimensions, Inc. is a US-based company specializing in innovative cardiac therapies, focusing on improving the quality of life for patients with heart failure through advanced medical devices.Cardiac Dimensions, Inc. develops cardiac therapies, particularly the Carillon Mitral Contour System to treat functional mitral regurgitation. Founded in 2001 in Kirkland, US, the company has executed 16 deals, with the most recent being a Series E funding round in March 2025. The funding raised USD 53.00 mn, led by Ally Bridge Group, alongside other investors such as Claret Capital Partners and continuing partners like Hostplus and M.H. Carnegie & Co. The company operates from Kirkland and is focused on expanding its reach in the healthcare market.Cardiac Dimensions specializes in the development of innovative cardiac therapies, primarily focusing on the Carillon Mitral Contour System. This device addresses functional mitral regurgitation and aims to improve the overall quality of life for heart failure patients suffering from this condition. The Carillon system harmonizes with the heart's natural structure, offering a less invasive treatment option that enhances patient outcomes and reduces hospitalizations. The company primarily serves healthcare professionals and institutions, particularly in Europe where the Carillon system is CE marked and commercially available, while also exploring opportunities in other international markets recognizing the CE mark.Cardiac Dimensions generates revenue through the sale of its Carillon Mitral Contour System and associated therapies to hospitals and healthcare providers. Transactions are structured around direct sales to medical institutions, reflecting the advanced technology and clinical benefits of the device. The company may also engage in partnerships with healthcare systems, providing training and support for implementing their devices in clinical settings. The focus on innovative therapies for patients with heart failure contributes to ongoing revenue growth, positioning the company within the medtech landscape.In March 2025, Cardiac Dimensions raised USD 53.00 mn in Series E funding, led by Ally Bridge Group to support the completion of the EMPOWER Trial U.S. pivotal study and to aid in the continued commercialization of the innovative Carillon Mitral Contour System. The company is focused on launching new products and expanding into markets that recognize the CE mark, ensuring broader access to its therapies. Plans are in place to enhance its global presence by targeting additional international markets throughout 2025.

## Funding rounds

- Series E, Mar 20, 2025, $53M — Hostplus, M.H. Carnegie & Co, Ally Bridge Group, Claret Capital Partners, Lumira Ventures, Horizon 3 Healthcare
- Series D, Jan 5, 2023, $35M — EQT Life Sciences, Hostplus, Arboretum Ventures, M.H. Carnegie & Co, Lumira Ventures, Horizon 3 Healthcare
- Series C, Sep 29, 2020, $18M — EQT Life Sciences, Aperture Venture Partners, Hostplus, Arboretum Ventures, M.H. Carnegie & Co, Lumira Ventures
- Series D, Jul 22, 2011 — Polaris Partners
- Series D, Dec 18, 2007, $35M — Frazier Healthcare Partners, InterWest Partners, Polaris Partners, Johnson & Johnson Innovation, MPM BioImpact, Mitsubishi UFJ Capital, West River Group, Lumira Ventures
- Series C, Mar 17, 2004, $15M — Frazier Healthcare Partners, InterWest Partners, Polaris Partners, MPM BioImpact
- Series B, Jun 25, 2002, $12M — InterWest Partners, Polaris Partners, MPM BioImpact

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series B, Series C, Series D
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series B, Series C, Series D
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series B, Series C, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series C, Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series D
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series D
- West River Group — Series D
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series D, Series C, Series E
- EQT Life Sciences (https://capitalatlas.ai/funds/eqt-life-sciences) — Series C, Series D
- Aperture Venture Partners (https://capitalatlas.ai/funds/aperture-venture-partners) — Series C
- Hostplus — Series C, Series D, Series E
- Arboretum Ventures (https://capitalatlas.ai/funds/arboretum-ventures) — Series C, Series D
- M.H. Carnegie & Co (https://capitalatlas.ai/funds/m-h-carnegie-co) — Series C, Series D, Series E
- Horizon 3 Healthcare (https://capitalatlas.ai/funds/horizon-3-healthcare) — Series D, Series E
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series E
- Claret Capital Partners (https://capitalatlas.ai/funds/claret-capital-partners) — Series E